文献速递前列腺癌

并非所有不良病理特征都等同:识别根治性前列腺切除术后不良病理患者中辅助放疗的最佳候选者

Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
PubMed 文献 · J Urol · 2022-07-05

在8362例接受根治性前列腺切除术的患者中,926例具有不良病理特征(分级组4-5且≥pT3a期和/或淋巴结侵犯)。Cox模型对每个特征赋分后分为低、中、高危组,交互分析显示仅高危组从辅助放疗中显著获益(10年总生存率76% vs 63%,P=0.038)。

要点

  • 不良病理特征患者可分为低、中、高危三个亚组。
  • 仅高危组辅助放疗较高危组观察±早期挽救放疗显著改善10年总生存(76% vs 63%,P=0.038)。
  • 低、中危组辅助放疗与观察±早期挽救放疗的10年总生存相当。

核心结论

  • 在具有不良病理特征的患者中,识别出3个风险亚组;仅高危组患者似乎从辅助放疗中获益。

研究设计与样本

  • 单中心1987年至2020年间8362例接受根治性前列腺切除术的患者中,识别出926例具有不良病理特征(分级组4-5且≥pT3a期和/或淋巴结侵犯)的合格患者,采用Cox模型对每个特征赋分,将患者分为低、中、高危组,并在逆概率治疗加权调整后行交互项分析检验辅助放疗对各风险亚组的影响。

主要发现

  • 538例(58%)接受辅助放疗,89例(10%)接受早期挽救放疗,299例(32%)接受观察;10年总生存率为90%。
  • 辅助放疗与高危组之间存在显著交互作用(HR 0.21,P=0.04)。
  • 风险分层和倾向评分加权后,低危和中危患者接受辅助放疗或观察±早期挽救放疗的10年总生存相当。
  • 高危患者中,辅助放疗较观察±早期挽救放疗显著改善10年总生存(76% vs 63%,P=0.038)。

关键数值与推荐

  • 不良病理特征定义为分级组4-5且≥pT3a期和/或淋巴结侵犯。
  • 高危组辅助放疗较观察±早期挽救放疗的10年总生存:76% vs 63%(P=0.038)。
  • 辅助放疗与高危组交互作用:HR 0.21(P=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent studies reported a potential benefit associated with adjuvant radiotherapy for patients with adverse pathology features of prostate cancer. We hypothesized that not all the patients with adverse features may benefit from adjuvant radiotherapy and, therefore, observation ± early salvage radiotherapy may still be considered in a subgroup of these patients. MATERIALS AND METHODS: Among 8,362 patients treated with radical prostatectomy at a single center between 1987 and 2020, 926 eligible patients with adverse pathology features (ie, grade group 4-5 with ≥pT3a stage and/or lymph node invasion) were identified. Cox models were used to assign a score to each feature. Patients were then stratified in low-, intermediate-, and high-risk groups, and interaction term analyses tested the impact of adjuvant radiotherapy for each risk subgroup after adjusting for inverse probability of treatment weighting. RESULTS: Overall, 538 (58%) vs 89 (10%) vs 299 (32%) patients received adjuvant radiotherapy vs early salvage radiotherapy vs observation. The 10-year overall survival rate was 90%. A significant interaction between adjuvant radiotherapy and high-risk group was recorded (HR 0.21, P = .04). After risk stratification and propensity-score weighting, survival analyses depicted comparable 10-year overall survival in low- and intermediate-risk patients treated with adjuvant radiotherapy or observation ± early salvage radiotherapy. Conversely, in high-risk patients, adjuvant radiotherapy was associated with significant improvement in 10-year overall survival compared to observation ± early salvage radiotherapy (76% vs 63%, P = .038). CONCLUSIONS: Among patients with adverse pathology features, we identified 3 subclassifications of risk. When testing the effect of adjuvant radiotherapy vs observation with or without early salvage radiotherapy on survival, only patients included in the high-risk group seemed to benefit from adjuvant radiotherapy.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mazzone E, Gandaglia G, Stabile A, et al. Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. J Urol. 2022. PMID: 35830554. doi:10.1097/JU.0000000000002855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。